Answer
Inaqovi’s decitabine component is believed to act after phosphorylation and incorporation into DNA by inhibiting DNA methyltransferase, causing DNA hypomethylation that may restore normal function to genes controlling cellular differentiation and proliferation in neoplastic cells.
Sources for this answer
- Inaqovi 35 mg/100 mg film coated tabletsOtsuka Pharmaceuticals (UK) Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 2Document updated
Sources checked